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Efficacy of Statin Therapy in 
Pulmonary Arterial Hypertension: 
A Systematic Review and Meta-
Analysis
Magdalena Rysz-Górzynska1,2, Anna Gluba-Brzózka2,3, Amirhossein Sahebkar4,5, Maria-
Corina Serban6,7, Dimitri P. Mikhailidis8, Sorin Ursoniu9, Peter P. Toth10,11, Vera Bittner6, 
Gerald F. Watts12, Gregory Y. H. Lip13, Jacek Rysz2,3, Alberico L. Catapano14 & Maciej Banach1,2
Since the evidence regarding statin therapy in PAH has not been conclusive, we assessed the impact 
of statin therapy in PAH through a systematic review and meta-analysis of available studies. We 
searched selected databases up to August 1, 2015 to identify the studies investigating the effect of 
statin administration on PAH. Meta-analysis was performed using either a fixed-effects or random-
effect model according to I2 statistic. Meta-analysis of 8 studies with 665 patients did not suggest any 
significant improvement in 6-min walking distance (6MWD) by statin therapy (weighed mean difference 
[WMD]: −6.08 m, 95% confidence interval [CI]: −25.66, 13.50, p = 0.543; Q = 8.41, I2 = 28.64%). 
Likewise, none of the other indices including pulmonary arterial pressure (WMD: −0.97 mmHg, 95%CI: 
−4.39, 2.44, p = 0.577; Q = 14.64, I2 = 79.51%), right atrial pressure (WMD: 1.01 mmHg, 95%CI: −0.93, 
2.96, p = 0.307; Q = 44.88, I2 = 95.54%), cardiac index (WMD: 0.05 L/min/m2, 95%CI: −0.05, 0.15, 
p = 0.323; Q = 3.82, I2 = 21.42%), and pulmonary vascular resistance (WMD: −1.42 dyn*s/cm5, 95%CI: 
−72.11, 69.27, p = 0.969; Q = 0.69, I2 = 0%) was significantly altered by statin therapy. In conclusion, 
the results of the meta-analysis did not show a statistically significant effect of statin therapy in the 
improvement of 6MWD, pulmonary arterial pressure, right atrial pressure, cardiac index and pulmonary 
vascular resistance.
Pulmonary hypertension (PAH) is defined according to the new 2015 Guidelines of the European Society of 
Cardiology (ESC) and European Respiratory Society (ERS) as an increase of the mean pulmonary arterial pres-
sure (PAPm) above 25 mmHg at rest, assessed by right heart catheterization (RHC) and pulmonary vascular 
resistance (PVR) above 3 Wood units1. Compared with the 2008 PAH guidelines, the new guidelines eliminated 
the exercise criterion, added hemodynamic parameters, and defined post-capillary PAH subgroups1. The new 
guidelines categorized various PAH conditions into five groups: pulmonary arterial hypertension, pulmonary 
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hypertension due to left heart disease, pulmonary hypertension due to lung diseases and/or hypoxia, chronic 
thromboembolic pulmonary hypertension and other pulmonary artery obstructions, and pulmonary hyperten-
sion with unclear and/or multifactorial mechanisms1. Several prognostic factors such as right ventricular failure, 
higher World Health Organization functional classification (WHO FC), shorter 6-min walk distance (6MWD) 
and hemodynamic factors such as right atrial pressure, and brain natriuretic peptide (BNP) levels are useful for 
PAH prognosis2,3. Furthermore, the American College of Chest Physicians’ (CHEST) Guideline suggests that the 
diagnosis of PAH should be made in a systematic and consistent manner with the use of a combination of WHO 
FC, exercise capacity, echocardiographic, laboratory and hemodynamic variables, and care should be provided 
by experts in the management of PAH. (Grade CB)4. However, the prognosis for patients with PAH remains poor, 
especially without appropriate treatment5.
Current therapy for PAH is based on endothelin receptor antagonists, phosphodiesterase-5 (PDE5) inhib-
itors, prostacyclin analogues (prostanoids), soluble guanylate cyclase stimulators, and prostacyclin receptor 
(IP receptor) agonist6,7. Despite the appearance of novel targets for PAH therapy tested in preclinical and clinical 
trials such as rituximab, endothelial progenitor cells, specific rho-kinase (ROCK) inhibitors (AT-877ER), FK506 
(tacrolimus), fluoxetine, sertraline, paroxetine, bardoxolone methyl, aviptadil or tyrosine kinase inhibitors (nilotinib, 
sorafenib and imatinib), the diagnosis and treatment of PAH is still difficult7.
The pleiotropic effects of statins through induction of endothelial nitric oxide (NO) expression as well as 
anti-inflammatory and antiproliferative mechanisms possibly confer various clinical advantages beyond the 
reduction of serum cholesterol levels8,9. Since statins have been suggested as potential drugs for PAH treat-
ment10, we assessed the impact of statin therapy on multiple parameters in PAH in this systematic review and 
meta-analysis.
Methods
This study was designed according to the 2009 preferred reporting items for systematic reviews and meta-analysis 
(PRISMA) guidelines11. Due to the study design (meta-analysis) no Institutional Review Board (IRB) approval, as 
well as no patients’ informed consents were obtained.
Search Strategy. PubMed-Medline, SCOPUS, Web of Science and Google Scholar databases were searched 
using the following search terms in titles and abstracts (also in combination with MESH terms): (atorvastatin 
OR simvastatin OR rosuvastatin OR fluvastatin OR pravastatin OR pitavastatin OR lovastatin OR cerivastatin 
OR “statin therapy” OR statins OR statin) AND (“pulmonary arterial hypertension” OR “pulmonary hyperten-
sion” OR “pulmonary artery hypertension” OR “pulmonary vascular disease” OR “pulmonary heart disease” OR 
“pulmonary cardiac disease” OR PAH). The wild-card term “* ” was used to increase the sensitivity of the search 
strategy. The literature search was limited to articles published in English. The search was limited to studies in 
humans. The literature was searched from inception to August 1, 2015. Two reviewers (MRG and AGB) evaluated 
each article independently. Disagreements were resolved by discussion with a third party (MB).
Study Selection. Original studies were included if they met the following criteria: (i) being a clinical study 
with either observational or interventional design, (ii) recruiting patients with a clinical diagnosis of PAH accord-
ing to echocardiography regardless of the etiology (congenital heart disease, connective tissue disease, chronic 
thrombembolism or iatrogenic), and, (iii) investigating the impact of statin therapy on a valid disease activity 
index including 6MWD, pulmonary arterial pressure, right atrial pressure, cardiac index and pulmonary vascular 
resistance.
Exclusion criteria were: (i) non-clinical studies, (ii) lack of a statin-free control group in the study design, and, 
(iii) lack of sufficient information on baseline or follow-up indices of PAH.
Data extraction. Eligible studies were reviewed and the following data were abstracted: 1) first author’s 
name 2) year of publication 3) study location 4) study design 5) number of participants in the statin and groups 5) 
age, gender and body mass index (BMI) of study participants 6) type and duration of statin therapy and 7) base-
line and follow-up values of PAH-related indices.
Data extraction was performed independently by 2 reviewers; disagreements were resolved by a third reviewer.
Quality assessment. Methodological quality of the included studies was assessed using the Newcastle-Ottawa 
Scale (NOS)12. In this context, topic items of each eligible study are assessed: that is, the selection of the studied 
patients, the comparability of the studied populations and the ascertainment of the exposure. A study can be 
awarded a maximum of one point for each item. Risk-of-bias assessment was performed independently by 2 
reviewers; disagreements were resolved by a third reviewer.
Quantitative Data Synthesis. Meta-analysis was conducted using Comprehensive Meta-Analysis (CMA) 
V2 software (Biostat, NJ)13. Net changes in measurements (change scores) were calculated as follows: measure at 
end of follow-up − measure at baseline. For single-arm cross-over trials, net change in each efficacy measure was 
calculated by subtracting the value after control intervention from that reported after treatment. Standard devia-
tions (SDs) of the mean difference were calculated using the following formula: SD = square root [(SDpre-treatment)2 
+ (SDpost-treatment)2 − (2R × SDpre-treatment × SDpost-treatment), assuming a correlation coefficient (R) = 0.5. If the out-
come measures were reported in median and range or 95% CI, mean and standard SD values were estimated 
using the method described by Wan et al.14. Where standard error of the mean (SEM) was only reported, SD was 
estimated using the following formula: SD = SEM × sqrt (n), where n is the number of subjects.
A random-effects model (using DerSimonian-Laird method) and the generic inverse variance method were 
used to compensate for the heterogeneity of studies in terms of demographic characteristics of populations being 
studied and also differences in study design and type of statin being studied15. Heterogeneity was quantitatively 
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assessed using I2 index. Effect sizes were expressed as weighted mean difference (WMD) and 95% confidence 
interval (CI). In order to evaluate the influence of each study on the overall effect size, sensitivity analysis was 
conducted using leave-one-out method, i.e. removing one study each time and repeating the analysis.
Publication bias. Potential publication bias was explored using visual inspection of Begg’s funnel plot asym-
metry, Begg’s rank correlation, and Egger’s weighted regression. Duval and Tweedie “trim and fill” was used to 
adjust the analysis for the effects of publication bias16.
Results
Flow and characteristics of included studies. On the basis of a database search 859 published studies 
were found, 310 of which were non-clinical or review articles and thus they were not included in further analysis. 
We screened 549 articles but 533 of them were excluded because they did not meet inclusion criteria. Out of 16 
eligible papers, 6 were excluded since they were not conducted in subjects with PAH, one of them did not assess 
any of the pre-specified efficacy measures, and one was not a clinical study. Finally, we included 8 articles in this 
meta-analysis17–24 (Fig. 1).
Most of the analyzed studies (7/8) were randomized, double- or triple-blind and placebo-controlled. This 
meta-analysis comprised 665 patients with PAH receiving either statins (rosuvastatin, simvastatin, pravastatin 
or atorvastatin) (311 patients) or placebo (354 patients) for 6 months. In analyzed patients, PAH was idiopathic, 
heritable, associated with congenital heart disease, atrial-septal defects or connective tissue disease, and many of 
them suffered from chronic obstructive pulmonary disease. The PAH-related indices 6MWD, pulmonary arterial 
pressure, right atrial pressure, cardiac index and pulmonary vascular resistance were measured in 6, 6, 2, 4 and 2 
analyzed studies, respectively (Table 1).
Risk of bias assessment. The quality of the included studies assessed by the Newcastle-Ottawa Scale 
(NOS)12 is shown in Table 2.
Effect of statin therapy on PAH-related indices. Meta-analysis of included studies did not suggest 
any significant improvement in 6MWD by statin therapy (WMD: − 6.08 m, 95% CI: − 25.66, 13.50, p = 0.543; 
Q = 8.41, I2 = 28.64%) (Fig. 2A). This effect was robust in sensitivity analysis and the statistical significance was 
not influenced by any single study included in the meta-analysis (Fig. 2B). Likewise, none of the other indi-
ces including pulmonary arterial pressure (WMD: − 0.97 mmHg, 95% CI: − 4.39, 2.44, p = 0.577; Q = 14.64, 
I2 = 79.51%) (Fig. 3A), right atrial pressure (WMD: 1.01 mmHg, 95% CI: − 0.93, 2.96, p = 0.307; Q = 44.88, 
I2 = 95.54%) (Fig. 3B), cardiac index (WMD: 0.05 L/min/m2, 95% CI: − 0.05, 0.15, p = 0.323; Q = 3.82, 
I2 = 21.42%) (Fig. 3C), and pulmonary vascular resistance (WMD: − 1.42 1.42 dyn* s/cm5, 95% CI: − 72.11, 69.27, 
p = 0.969; Q = 0.69, I2 = 0%) (Fig. 3D) was significantly altered by statin therapy.
Publication bias. The funnel plot of the study standard error by effect size (mean difference) for the 
meta-analysis of statin effects on 6MWD was asymmetric suggesting a potential publication bias (Fig. 4). Using 
“trim and fill” correction, two potentially missing studies were imputed on the left side of funnel plot, yielding 
an effect size of − 11.72 m (95% CI: − 31.27, 7.82). The results of Begg’s rank correlation (Kendall’s Tau with 
continuity correction = 0.38, z = 1.20, two-tailed p-value = 0.230) and Egger’s linear regression (intercept = 1.97, 
standard error = 1.25; 95% CI = − 1.24, 5.18, t = 1.58, df = 5, two-tailed p = 0.176) tests excluded the possibility 
of publication bias in the meta-analyses.
Figure 1. Flow chart of the number of studies identified and included into the meta-analysis. 
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First author’s 
name Barreto et al.17 Kawut et al.18 Lee et al.19 Liu et al.20 Moosavi et al.21 Reed et al.22 Wilkins et al.23 Zeng et al.24
Year of 
publication 2008 2011 2009 2013 2013 2011 2010 2012
Study location Brazil USA Taiwan China Iran USA Germany China
Study design
Randomized, 
double-blind, 
placebo-
controlled 
study
4-center, 
randomized, 
double-blind, 
placebo-
controlled 
study
Randomized, 
double-blind 
parallel, 
placebo-
controlled 
trial
Randomized, 
placebo-
controlled trial
Randomized, 
triple-blind, 
parallel-group 
trial
Cohort, retrospective, 
cross-sectional, non-
randomized
Randomized, double-
blind, placebo-
controlled trial
Randomized, double-
blind and placebo-
controlled trial
Inclusion criteria
Idiopathic or 
congenital 
heart disease-
associated 
PAH (WHO 
functional 
class I–III) in 
the absence 
or presence 
of hypoxemia 
with a mean 
PAP > 
30 mmHg at 
rest.
Pts. > 18 years 
of age with 
PAH (WHO 
functional 
class I–III).
COPD 
patients at 
age between 
40 and 80 years 
with PAH, 
provided 
conditions 
were stable 
for at least 
3 months.
60 to 85 years 
of age; in the 
stable chronic 
pulmonary 
heart disease 
with FEV1 ≤ 
65% of the 
predicted 
value, the ratio 
of FEV1 to the 
forced vital 
capacity was 
≤ 70% and 
PAH was > 
30 mmHg; and 
NYHA class I 
or II.
PAP > 
40 mmHg, 
able to doing 
6-MWD test, 
obstructive 
pattern in PFT 
and functional 
NYHA class II 
or III.
COPD patients evaluated 
for lung transplantation 
with PAH with mean 
PAP at rest > 25 mmHg.
Stable patients with 
class II or III PAH with 
mean PAP at rest > 
25 mm Hg, pulmonary 
capillary wedge 
pressure < 15 mmHg 
and pulmonary 
vascular resistance > 
3 Wood units; with 
a 6-MWD between 
150–500 m at entry.
18–65 years of age 
pts. with Class 
1 PAH defined 
as mean PAP > 
25 mmHg, pulmonary 
capillary wedge 
pressure < 15 mmHg 
and pulmonary 
vascular resistance > 
3 Wood units.
Number of 
participants in the 
statin group
30 32 27 33 24 34 19 112
Number of 
participants in the 
placebo group
30 33 26 35 21 78 23 108
Age of statin 
group 34.6 ± 12.3 51.7 ± 13.0 71 ± 8 66.2 ± 7.4 65 ± 11 58 ± 6 43.2 (19–67) 35 ± 13
Age of placebo 
group 33.7 ± 11.1 50.0 ± 14.3 72 ± 6 64.9 ± 8.2 68 ± 14 55 ± 9 49.1 (24–73) 37 ± 13
Gender of statin 
group
36 females, 24 
males
26 females, 6 
males
7 females, 20 
males
13 females, 20 
males
9 females, 15 
males 17 females, 17 males 17 females, 2 males 79 females, 33 males
Gender of placebo 
group
30 females, 3 
males
7 females, 19 
males
12 females, 23 
males
8 females, 13 
males 49 females, 29 males 15 females, 8 males 65 females, 43 males
Body mass index 
(BMI) of statin 
group
NA 28.1 ± 7.7 22 ± 2 NA NA 25 ± 5 24.4 ± 4.7 NA
Body mass index 
(BMI) of placebo 
group
NA 28.6 ± 7.8 23 ± 1 NA NA 24 ± 5 26.3 ± 3.3 NA
Type of statin 
therapy rosuvastatin simvastatin pravastatin atorvastatin atorvastatin atorvastatin, simvastatin simvastatin atorvastatin
Duration of statin 
therapy 6 months 6 months 6 months 6 months 6 months NA 24 weeks 24 weeks
Baseline 6MWD 
(m) values in 
statin group 
416 ± 103 422.9 ± 101.4 NA NA 238 ± 124 259 ± 94 381 ± 69 (198–498) 355 ± 74
Follow-up 
6MWD (m) 
values in statin 
group 
no increase no difference NA NA 339 ± 155 NA increased by 3.1 ± 34.5
decreased by 52  
(− 103– − 1)* * 
increased by 10  
(− 19–39)* * * 
Baseline 6MWD 
(m) values in 
placebo group
415 ± 110 418.3 ± 131.7 NA NA 284 ± 100 243 ± 120 386 ± 110 (120–600) 346 ± 84
Follow-up 
6MWD (m) 
values in placebo 
group
no increase NA NA NA 340 ± 106 NA increased by 1.0 ± 57.0
decreased by 79 
(− 126– − 33)* 
* increased by 50 
(31–69)* * * 
Baseline values 
of pulmonary 
arterial pressure 
(mmHg) in statin 
group
53 ± 16
NA 47 ± 8 52.7 ± 8.1 NA 26 ± 7 55.8 ± 10.3 (42–71) 69 ± 19
Baseline values 
of pulmonary 
arterial pressure 
(mmHg) in 
placebo group
NA 47 ± 7 51.7 ± 7.9 NA 29 ± 7 55.7 ± 12.5 (30–81) 66 ± 20
Continued
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First author’s 
name Barreto et al.17 Kawut et al.18 Lee et al.19 Liu et al.20 Moosavi et al.21 Reed et al.22 Wilkins et al.23 Zeng et al.24
Follow-up values 
of pulmonary 
arterial pressure 
(mmHg) in statin 
group
NA NA 40 ± 6 45.4 ± 6.8 NA decreased by 5.2 mmHg NA
increased by 4 
(0–7)* increased by 11 
(4–19)* * not changed 
0 (− 5–4)* * * 
Follow-up values 
of pulmonary 
arterial pressure 
(mmHg) in 
placebo group
NA NA 46 ± 7 49.1 ± 7.3 NA NA NA
increased by 3  
(− 1–6)* increased by 
10 (4–16)* * decreased 
by 5 (− 10–0)* * * 
Baseline values 
of right atrial 
pressure in statin 
group
NA NA NA NA NA 8.6 ± 5 NA 9 ± 6
Baseline values 
of right atrial 
pressure in 
placebo group
NA NA NA NA NA 10.3 ± 5 NA 10 ± 6
Follow-up values 
of right atrial 
pressure in statin 
group
NA NA NA NA NA NA NA
increased by 3 (2–5)* 
increased by 6 (2–9)* * 
increased by 3  
(1–5)* * * 
Follow-up values 
of right atrial 
pressure in 
placebo group
NA NA NA NA NA NA NA
increased by 3 (2–5)* 
increased by 5 (3–7)* * 
increased by 0  
(− 2–2)* * * 
Baseline values 
of cardiac index 
(l/m2) in statin 
group
NA NA 4.09 ± 0.49 NA NA 2.8 ± 0.6 2.6 ± 0.65 2.4 ± 0.8
Baseline values 
of cardiac index 
(l/m2) in placebo 
group
NA NA 4.33 ± 0.55 NA NA 2.9 ± 0.7 2.5 ± 0.7 2.6 ± 1
Follow-up values 
of cardiac index 
(l/m2) in statin 
group
NA NA 4.23 ± 0.33 NA NA NA increased by 0.12 ± 0.58
decreased by 0.1 
(–0.2–0)* decreased 
by 0.3 (− 0.5–0)* * not 
changed 0  
(− 0.1–0.2)* * * 
Follow-up values 
of cardiac index 
(l/m2) in placebo 
group
NA NA 4.26 ± 0.38 NA NA NA decreased by 0.05 ± 0.59
decreased by 0.2 
(− 0.3–0)* decreased 
by 0.4 (− 0.6– − 0.2)* * 
not changed 0  
(− 0.3–0.3)* * * 
Baseline values 
of pulmonary 
vascular 
resistance (dyn* 
s* cm−5) in statin 
group
NA NA NA NA NA 5.0 ± 2.6 NA 1633 ± 745
Baseline values 
of pulmonary 
vascular 
resistance (dyn* 
s* cm−5) in 
placebo group
NA NA NA NA NA 5.0 ± 2.2 NA 1456 ± 699
Follow-up values 
of pulmonary 
vascular 
resistance (dyn* 
s* cm−5) in statin 
group
NA NA NA NA NA NA NA
increased by 203 
(42–364)* increased 
by 440 (119–762)* 
* increased by 46 
(− 151–243)* * * 
Follow-up values 
of pulmonary 
vascular 
resistance (dyn* 
s* cm−5) in 
placebo group
NA NA NA NA NA NA NA
increased by 287 
(132–442)* increased 
by 605 (313–897)* 
* increased by 8 
(− 150–165)* * * 
Table 1.  Main characteristics of the included studies. Data are presented as mean ± SD and range in brackets. 
ABBREVIATIONS: 6-MWD – 6 minutes walk distance; COPD – chronic obstructive pulmonary disease; 
FEV1 – forced expiratory volume in one second % of vital capacity; NYHA - New York Heart Association; 
PAH – pulmonary arterial hypertension; PAP – pulmonary arterial pressure; PFT - pulmonary function test; 
WHO – world health organization; *mean change; * * change in patients with idiopathic pulmonary arterial 
hypertension and pulmonary arterial hypertension associated with connective tissue disorder; * * * change in 
patients with pulmonary arterial hypertension associated with congenital heart disease.
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Discussion
To our knowledge, the current systematic review and meta-analysis is the first to evaluate the effects of statins on 
PAH. Contrary to the findings from some studies18,25, this meta-analysis of 8 studies did not suggest any signif-
icant improvement in 6MWD, pulmonary arterial pressure, right atrial pressure, cardiac index, and pulmonary 
vascular resistance by statin therapy. The lack of benefit was robust in sensitivity analysis and the statistical signif-
icance was not influenced by any single study included in the meta-analysis.
These findings are of clinical interest, since the use of statins in PAH treatment is thought to be beneficial due 
to their antiproliferative, anti-inflammatory, and pro-apoptotic pleiotropic effects as well as the ability to restore 
endothelial vasoactive mediator production26. Various studies linked statin effects with the pathogenesis of pul-
monary hypertension and various biomarkers27, through analyzing the relation between statins, endothelin-1 
and PAH28,29, statins, asymmetric dimethylarginine and PAH30–32, statins, D-dimers and PAH33,34, statins, von 
Willebrand factor antigen and PAH35,36 or fibrinogen and PAH37,38. Until now, the results obtained using statins 
on PAH parameters in different animal models have been contradictory. Some experimental studies suggested 
that statins might attenuate the development or even regress established experimental PAH by decreasing pro-
liferation and increasing apoptosis of pathological smooth muscle cells in the medial walls and neointima of 
Domain and Topic (max. 10 stars)
Author Year
Selection (max. 5 stars) Comparability (max. 2 stars) Outcome (max. 3 stars)
Total
Representativeness 
of the sample
Sample 
size
Non-
responders
Ascertainment 
of the exposure
Subjects in different outcome 
groups are comparable
Assessment 
of Outcome
Choice of 
statistical 
tests
Barreto et al.17 2008 ★ ★ ★ ★ ★ ★ ★ 7
Kawut et al.18 2011 ★ ★ ★ ★ ★ ★ ★ ★ ★ 9
Lee et al.19 2009 ★ ★ ★ ★ ★ ★ ★ ★ ★ 9
Liu et al.20 2013 ★ ★ ★ ★ ★ ★ ★ 7
Moosavi et al.21 2013 ★ ★ ★ ★ ★ ★ ★ ★ 8
Reed et al.22 2011 ★ ★ ★ ★ ★ ★ ★ ★ 8
Wilkins et al.23 2010 ★ ★ ★ ★ ★ ★ ★ ★ 8
Zeng et al.24 2012 ★ ★ ★ ★ ★ ★ ★ ★ ★ 9
Table 2.  The quality of the studies assessed using Newcastle-Ottawa Scale.
Figure 2. Forest plot detailing weighted mean difference and 95% confidence intervals for the impact of 
statin therapy on 6-min walking distance (Fig. 2A). Lower plot (Fig. 2B) shows leave-one-out sensitivity 
analysis.
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pulmonary arteries and reducing right ventricular hypertrophy39,40. Other experimental studies on murine mod-
els reported an inhibition of progression of emphysema and pulmonary hypertension related to tobacco exposure 
after statin therapy41,42. One experimental study showed that low doses of fluvastatin have beneficial effects on 
adventitial fibroblasts from chronic hypoxic animals through actions on the Rac1-p38 MAP kinase-signaling 
pathway43. Another experimental study showed that rosuvastatin improved ischemia-reperfusion injury by 
decreasing macrophage infiltration and up-regulating endothelial nitric oxide synthase44. In contrast, atorvastatin 
neither improved survival nor reduced PAH, vascular remodeling and right ventricular hypertrophy in an exper-
imental study on a rat monocrotaline PAH model45. However, some experimental studies reported a decrease 
of right ventricular (RV) hypertrophy associated with statin therapy in PAH models46, but no study showed a 
reduction in pulmonary arterial pressure47,48. An experimental study on guinea pigs exposed to cigarette smoking 
during 6 months showed no effects of simvastatin on small airway remodeling49.
Figure 3. Forest plot detailing weighted mean difference and 95% confidence intervals for the impact 
of statin therapy on pulmonary arterial pressure (PAH) (Fig. 3A), right atrial pressure (RAP) (Fig. 3B), 
cardiac index (Fig. 3C), and pulmonary vascular resistance (PVR) (Fig. 3D).
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The data on humans from short-term randomized trials are few and contradictory. In an open-label observa-
tional trial, simvastatin was successfully used as adjunctive therapy in patients with PAH associated with various 
pathologies25. In another study, atorvastatin reduced pulmonary artery pressure and raised the migration and 
adhesion of endothelial progenitor cells (EPCs) in patients with chronic pulmonary heart disease20. Other studies 
described a decreased frequency of exacerbations and intubations50, a reduced decline of pulmonary function51 
and decreased pulmonary pressures associated with improved exercise capacity after statin treatment19 in patients 
with chronic obstructive pulmonary diseases. A multicenter propensity score study on 2,363 patients showed for 
the first time that statins improve survival in PAH patients by decreasing one-year all-cause mortality52.
Similar to our results obtained in this meta-analysis, and in contrast to previous arguments, another study 
did not find any effect of statins on 6MWD23, but the short duration of this trial and background therapy of PAH 
patients may be potential causes for the lack of effects. Another trial on 220 PAH patients showed no benefit of 
atorvastatin on cardio-pulmonary hemodynamics, 6 MWD and survival at 6 months of treatment24, suggesting 
that atorvastatin should not be prescribed as specific treatment in PAH.
Limitations. This meta-analysis has several limitations. First, the studies were relatively small and heteroge-
neous concerning study design, patients characteristics, major outcomes, PAH etiology and severity. Second, the 
patients included were classified in various functional classification groups. Third, the positive effects of statins 
in one study might have been overlapped by lack of effects of statins in the rest of studies since the effects of four 
statins (rosuvastatin, simvastatin, pravastatin and atorvastatin) were analyzed. Fourth, the patients received sup-
portive drugs such as diuretics, warfarin, and digoxin, which could have influenced the results. The follow-up 
of the study was relatively short (6 months), so the long-term effects cannot be concluded and it is possible that 
longer therapy with statin might have been effective. Taking into account the given small sample size and short 
duration of the included studies, the meta-analysis could not also look at CVD outcomes that would be of the 
greatest interest. Finally, in the most of included studies PAH was diagnosed mainly based on echocardiography, 
which is also an important limitation.
In conclusion, the results of this meta-analysis of available studies did not show a statistically significant effect 
of statin therapy in the improvement of 6 MWD, pulmonary arterial pressure, right atrial pressure, cardiac index 
and pulmonary vascular resistance. Additional large, long term and well-designed trials are necessary to inves-
tigate the impact of statins for the treatment of PAH including their use as pulmonary vascular antiproliferative 
agents.
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